Patient disposition
| Patients, n (%) . | Nilotinib 400 mg twice daily (n = 104) . | Imatinib 400-600 mg once daily (n = 103) . |
|---|---|---|
| Still on treatment | 80 (76.9) | 94 (91.3) |
| Discontinued | 24 (23.1) | 9 (8.7) |
| AE(s) | 12 (11.5) | 3 (2.9) |
| Withdrawal of consent | 6 (5.8) | 3 (2.9) |
| Death | 1 (1.0)* | 0 |
| Other† | 5 (4.8) | 3 (2.9) |
| Patients, n (%) . | Nilotinib 400 mg twice daily (n = 104) . | Imatinib 400-600 mg once daily (n = 103) . |
|---|---|---|
| Still on treatment | 80 (76.9) | 94 (91.3) |
| Discontinued | 24 (23.1) | 9 (8.7) |
| AE(s) | 12 (11.5) | 3 (2.9) |
| Withdrawal of consent | 6 (5.8) | 3 (2.9) |
| Death | 1 (1.0)* | 0 |
| Other† | 5 (4.8) | 3 (2.9) |
A 59-year-old male patient with a medical history of diabetes, hyperlipidemia, hypertension, and obesity who died due to suspected acute myocardial infarction.
Includes nonadherence with protocol or treatment, unacceptable toxicity, protocol violation, and transient loss of MMR (n = 1 each on nilotinib), pregnancy (imatinib), and unspecified (n = 1 nilotinib, n = 2 imatinib).